Bharat Biotech's Covaxin effective against Delta variant of coronavirus: Top US research institute
3 years, 6 months ago

Bharat Biotech's Covaxin effective against Delta variant of coronavirus: Top US research institute

India Today  

Covaxin, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research, effectively neutralises both Alpha and Delta variants of coronavirus, said the US' National Institute of Health. The results suggest that the vaccine generates antibodies that effectively neutralise the B.1.1.7 and B.1.617 variants of SARS-CoV-2, first identified in the UK and India, respectively, said the top American health research institute, NIH. "The results from two studies of blood serum from people who had received Covaxin suggest that the vaccine generates antibodies that effectively neutralise the B.1.1.7 and B.1.617 variants of SARS-CoV-2, first identified in the UK and India, respectively," the NIH said in its press release. ICMR Director General Balram Bhargava, in a press conference last week, said Covishield and Covaxin work against SARS-CoV-2 variants Alpha, Beta, Gamma and Delta, while effectiveness tests against the Delta Plus variant is ongoing.

India Variants Delta Vaccine Variant Nih Bharat Biotech Covaxin Niaid Efficacy Delta Variant Effective Bharat  effective  bharat  covaxin  covid19  institute  results  sarscov2  nih  efficacy  delta  biotechs  coronavirus  variants  phase  vaccine  variant  research

History of this topic

‘Safety is primary focus’: Covaxin-developer amid reports on AstraZeneca vaccine
8 months, 1 week ago

‘Safety is primary focus’: Covaxin-developer amid reports on AstraZeneca vaccine

Hindustan Times  

Amid reports over potential rare side effects of the AstraZeneca-Oxford COVID-19 vaccine, Bharat Biotech, which developed the Covaxin, said in a statement that the vaccine was developed with a "single-minded focus on safety first." It stated that Covaxin was the "only Covid vaccine" in government of India's COVID-19 immunisation program to have conducted efficacy trials in India. "@bharatbiotech announcement - …

AstraZeneca reaffirms Covid vaccine safety amid rare side effect concerns
8 months, 1 week ago

AstraZeneca reaffirms Covid vaccine safety amid rare side effect concerns

India TV News  

In response to recent concerns regarding potential rare side effects associated with the AstraZeneca-Oxford COVID-19 vaccine, the pharmaceutical company has underscored its unwavering commitment to patient safety while affirming the vaccine's overall safety profile. This comes in the wake of a recent admission by AstraZeneca, the pharmaceutical company, that its Covid vaccine Covishield and Vaxzevria "can, in very rare cases, …

Covishield more effective than Covaxin: Study
10 months ago

Covishield more effective than Covaxin: Study

New Indian Express  

BENGALURU: Covishield vaccine had higher antibody response compared to Covaxin during the pandemic, according to a study by a consortium of 11 institutions led by scientists from the National Centre for Biological Sciences, Bengaluru. In all, 691 people aged between 18 and 45, mostly from Bengaluru and Pune, were part of the study.’Immunogenicity of SARS - CoV-2 vaccines Covaxin and …

What study on Covishield versus Covaxin vaccine reveals
10 months ago

What study on Covishield versus Covaxin vaccine reveals

The Hindu  

March 07, 2024 10:59 am | Updated March 09, 2024 10:53 am IST - Bengaluru A new study by a consortium of 11 institutes, led by scientists from the National Centre for Biological Sciences, has found that the Covishield vaccine demonstrated more robust immune responses compared to Covaxin. The key findings state that Covishield, leveraging a virus vector to deliver …

IISc comes up with warm vaccine against current strains of SARS-CoV-2
11 months, 4 weeks ago

IISc comes up with warm vaccine against current strains of SARS-CoV-2

The Hindu  

A heat-tolerant vaccine developed by the Indian Institute of Science researchers is said to be effective against all current strains of SARS-CoV-2 besides having the potential to be quickly adapted for future variants as well. According to IISc-Bengaluru, since the beginning of the COVID-19 pandemic, Prof. Raghavan Varadarajan from the institute’s Molecular Biophysics Unit and collaborators have been working on …

New COVID variant JN.1: Health Ministry says no need for booster dose
1 year ago

New COVID variant JN.1: Health Ministry says no need for booster dose

The Hindu  

Following the Union Health Ministry direction that States be alert and prepared for any possible surge in COVID-19 cases following the emergence of the new variant JN.1, senior health officials said that there is no move to recommend administration of vaccine booster dose for India. India saw a single-day rise of 656 COVID-1 infections while the active cases have increased …

Studies show XBB.1.16 is not clinically more severe
1 year, 8 months ago

Studies show XBB.1.16 is not clinically more severe

Hindustan Times  

The XBB.1.16 sub-variant of the Omicron strain of the SARS-CoV-2 virus that causes Covid does not exhibit higher clinical severity according to preliminary results from laboratory studies being conducted in the country to know disease characteristics, according to people familiar with the matter. According to the World Health Organisation, mutations at position 478 of the SARS-CoV-2 spike protein have been …

Centre rolls out first nasal Covid vaccine as booster
1 year, 11 months ago

Centre rolls out first nasal Covid vaccine as booster

Hindustan Times  

India on Thursday rolled out the first nasal vaccine against Covid-19, to be administered as a primary or booster dose for adults, potentially widening the pool of people who may take a third vaccine against the infection, cutting tertiary costs, and easing pressures on supply and storage networks. “Being the world’s first intranasal Covid-19 vaccine, this marks a glorious tribute …

COVID-19: Mansukh Mandaviya launches world's 1st Made-in-India nasal vaccine iNCOVACC
1 year, 11 months ago

COVID-19: Mansukh Mandaviya launches world's 1st Made-in-India nasal vaccine iNCOVACC

India TV News  

COVID-19 nasal vaccine launch : Union Health Minister Dr Mansukh Mandaviya and Science and Technology Minister Jitendra Singh collectively launched 'iNCOVACC', the world's first made-in-India nasal vaccine on Thursday in the national capital. Who all were present: On the occasion of the launch, the Union Minister of State Science & Technology; Minister of State Earth Sciences; MoS PMO, Personnel, Public …

DCGI Approves Market Authorisation for SII's Covid Vaccine Covovax as Heterologous Booster Dose
1 year, 11 months ago

DCGI Approves Market Authorisation for SII's Covid Vaccine Covovax as Heterologous Booster Dose

News 18  

The Drug Controller General of India has approved market authorisation to COVID-19 vaccine Covovax as a heterologous booster dose for adults who have been administered two doses of Covishield or Covaxin, official sources said on Monday. Prakash Kumar Singh, Director of Government and Regulatory Affairs at the Serum Institute of India, had recently written to the DCGI for the approval …

Covishield Immune Responses Against Covid Variants Higher Than Covaxin: Study
2 years ago

Covishield Immune Responses Against Covid Variants Higher Than Covaxin: Study

News 18  

Neutralising antibody responses against the SARS-COV-2 virus and its variants of concern are higher among Covishield recipients than those who took the indigenously made Covaxin, according to a multi-centre study. Covishield elicited immune responses of higher magnitude and breadth than Covaxin in both seronegative individuals and seropositive individuals, across cohorts representing the pre-vaccination immune history of the majority of the …

Covid-19 new variant: ‘Transmissible, immune evasive, fatal’, says top scientist
2 years ago

Covid-19 new variant: ‘Transmissible, immune evasive, fatal’, says top scientist

Live Mint  

A top US scientist has revealed how fast the new variant of coronavirus has transmitted around the world. Eric Feigl-Ding, an epidemiologist and health economist said that the US government agency-the CDC--ignored the threats of the new variant, responsible for the high rate of hospitalisation. Ding said the XBB.1.5 variant of coronavirus has its root in the northeast US, and …

Can Your Vaccine Protect You Against BF.7? India Isolates New Strain, Begins Study to Test Efficacy
2 years ago

Can Your Vaccine Protect You Against BF.7? India Isolates New Strain, Begins Study to Test Efficacy

News 18  

A sample of SARS-CoV-2 virus containing the BF.7, a sub-lineage of the Omicron variant, has successfully been isolated by India to assess the efficacy of available vaccines. “Scientists are studying whether the currently available vaccines are effective in preventing infections or serious illness caused by the new sub-variant,” a source was quoted as saying. India has reported at least four …

Biological E, Bharat Biotech have stockpile of 250 million COVID vaccine doses
2 years ago

Biological E, Bharat Biotech have stockpile of 250 million COVID vaccine doses

India TV News  

As Covid cases are increasing in the country, now focus is back on vaccination drive. According to sources- two major vaccine makers from Hyderabad, Biological E Ltd and Bharat Biotech, together have about 250 million doses of COVID-19 vaccines ready to dispatch as and when orders are received. Corbevax and Covaxin stocks Biological E held 200 million doses of its …

What is Covid variant XBB? Is it severe among Indian patients like the previous coronavirus?
2 years ago

What is Covid variant XBB? Is it severe among Indian patients like the previous coronavirus?

India TV News  

The XBB subvariant of Covid-19's Omicron variant is fast emerging as the dominant type in India, and now it accounts for more than 18 per cent of cases in the US as well. According to the WHO, XBB is a recombined subvariant, a sub-lineage of the Omicron variants BA.2.10.1 and BA.2.75 which means it is a subvariant of the Covid-19 …

SII Seeks Drug Regulator's Nod for Market Authorisation of Covovax Vaccine as Covid-19 Booster Dose
2 years ago

SII Seeks Drug Regulator's Nod for Market Authorisation of Covovax Vaccine as Covid-19 Booster Dose

News 18  

The Serum Institute of India has sought the drug regulator’s approval for market authorisation of its COVID-19 vaccine Covovax as a booster dose for those aged 18 years and above who have been administered two doses of Covishield or Covaxin, official sources said on Thursday. Prakash Kumar Singh, director, government and regulatory affairs, SII, submitted a market authorisation application for …

A concerning sequence: The Hindu Editorial on a new coronavirus strain and a spurt in cases in China
2 years ago

A concerning sequence: The Hindu Editorial on a new coronavirus strain and a spurt in cases in China

The Hindu  

The spurt in coronavirus cases reported out of China has triggered global alarm. India’s Health Ministry has issued a directive to States to send positive samples to the Indian SARS-CoV-2 Genomics Consortium to check for new, concerning strains. There is scarce monitoring and mask mandates for public gatherings, airports and railway stations have been removed everywhere; so, low numbers do …

Bharat Biotech misstated Covaxin trial data
2 years, 1 month ago

Bharat Biotech misstated Covaxin trial data

Deccan Chronicle  

HYDERABAD: Extremely serious procedural leniencies and incorrect reporting of the results of trials of Covaxin, Bharat Biotech’s anti-Covid vaccine, have come to light, raising some very uncomfortable questions on the vaccine’s rollout for general use in India. Inquiries and investigation into the three phases of human trials of Covaxin have found grave reporting errors – some that appear to be …

CORBEVAX offers better immunity as a heterologous booster shot
2 years, 2 months ago

CORBEVAX offers better immunity as a heterologous booster shot

Deccan Chronicle  

HYDERABAD: Heterologous booster shots have gained significance in light of the waning effect of vaccine doses, especially against different variants of the Covid-19 virus. There is an increase in the immune response to the administration of heterologous booster shots on two counts – first cellular immunity and second, neutralizing antibodies. Administering the CORBEVAX vaccine as a heterologous booster dose provides …

Maharashtra govt warns of COVID-19 spike; new variants reported from state ahead of winter, festive season
2 years, 2 months ago

Maharashtra govt warns of COVID-19 spike; new variants reported from state ahead of winter, festive season

India TV News  

Highlights The health department has informed new variants BA.2.3.20 and BQ.1 have been reported from the state These variants have been detected for the first time in the country New XBB variant of coronavirus has a growth advantage over BA.2.75, it said Maharashtra health department has warned of a spike in the number of coronavirus cases in the state, especially …

Will Two ‘Made-in-India’ Vaccines Be the New Covid Boosters? News18 Decodes Differences
2 years, 3 months ago

Will Two ‘Made-in-India’ Vaccines Be the New Covid Boosters? News18 Decodes Differences

News 18  

India will soon roll out mRNA shots and intranasal vaccines, which will be available on CoWIN, and can be used as boosters against Covid-19. India’s first mRNA shot is only the third mRNA vaccine to be approved for Covid-19 in the world after Pfizer and Moderna. But mortality will be reduced.” Sharing a study of the intranasal vaccines under clinical …

India's First Nasal Vaccine for Covid-19, Made by Bharat Biotech, Cleared for Emergency Use
2 years, 4 months ago

India's First Nasal Vaccine for Covid-19, Made by Bharat Biotech, Cleared for Emergency Use

News 18  

Bharat Biotech has been given an emergency use authorisation by India’s drug regulator, the Drug Controller General of India, for its intranasal Covid-19 vaccine, Union Health Minister Dr Mansukh Mandaviya tweeted on Tuesday. Big Boost to India's Fight Against COVID-19!Bharat Biotech's ChAd36-SARS-CoV-S COVID-19 recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for restricted …

Tackling the new variants
2 years, 4 months ago

Tackling the new variants

Hindustan Times  

The first redesigned coronavirus vaccine was approved for use this week when authorities in the United Kingdom cleared a Moderna dose that the company adapted to create immunity against the Omicron variant. The vaccine is a 50-50 formulation of Moderna’s 2020 product, designed on the Sars-CoV-2 variant that first spread around the world, and of a new dose developed using …

Corbevax as Covid booster for adults from August 12. Check details
2 years, 4 months ago

Corbevax as Covid booster for adults from August 12. Check details

India Today  

In a boost to India’s fight against coronavirus, the government gave nod to Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin. Announcing the decision, Union Health minister Mansukh Mandaviya said, “Further Strengthening India's arsenal against Covid-19, Ministry of Health and Family Welfare approves Corbevax as precaution dose for those …

Corbevax approved as booster for those jabbed with Covishield, Covaxin: Report
2 years, 4 months ago

Corbevax approved as booster for those jabbed with Covishield, Covaxin: Report

Live Mint  

The government has approved Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin, news agency PTI has reported on 10 August citing official sources. "Corbevax will be considered as a precaution dose after completion of six months or 26 weeks from the date of administration of the second dose of …

In A First, Biological E's Corbevax Approved As Covid Booster for Covishield, Covaxin Recipients
2 years, 4 months ago

In A First, Biological E's Corbevax Approved As Covid Booster for Covishield, Covaxin Recipients

News 18  

The Centre has approved Biological E’s Corbevax as a Covid-19 precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin. Union Health Secretary Rajesh Bhushan said, “Corbevax will be available as precaution dose after completion of six months or 26 weeks from the date of administration of the second dose of either Covaxin or Covishield vaccines …

Govt Nod for Corbevax as Booster for Adults Vaccinated with Covishield, Covaxin Soon
2 years, 5 months ago

Govt Nod for Corbevax as Booster for Adults Vaccinated with Covishield, Covaxin Soon

News 18  

The Union health ministry is expected to soon approve Biological E’s Corbevax as a precaution dose for people above 18 years who are double vaccinated with either Covishield or Covaxin, official sources said on Tuesday. “Corbevax will be considered as a precaution dose after completion of 6 months or 26 weeks from the date of administration of the second dose …

Bharat Biotech expects regulator’s nod for intranasal COVID-19 vaccine this month
2 years, 5 months ago

Bharat Biotech expects regulator’s nod for intranasal COVID-19 vaccine this month

The Hindu  

Bharat Biotech, which is working on an intranasal COVID-19 vaccine candidate is hopeful of getting regulatory licenses this month, if all goes well, Chairman and Managing Director of the company, Krishna Ella said. Clinical trials of nasal vaccine complete Mr. Ella said the firm completed clinical trials of the nasal vaccine with about 4,000 volunteers and there is no instance …

Exclusive: Coming soon, second generation, variant specific anti-Covid vaccine
2 years, 5 months ago

Exclusive: Coming soon, second generation, variant specific anti-Covid vaccine

India Today  

The Centre has invested in developing a strain specific vaccine that would help in countering the changing nature of coronavirus. An official who facilitated developing this ecosystem for second generation vaccines told India Today that research and development work is underway to develop strain-specific vaccines in India. A bivalent vaccine will target the specific spike mutations seen in the Omicron …

Will Americans have the right COVID-19 vaccine this fall? Maybe
2 years, 5 months ago

Will Americans have the right COVID-19 vaccine this fall? Maybe

LA Times  

A man walks underneath the marquee of the Alex Theatre in Glendale. Determining which recipe should go into those doses to induce optimal protection — the vaccine’s “composition” — is an exercise in educated guesswork. Getting a timely and accurate fix on all this “is truly a challenge, and it is science at its hardest,” Dr. Peter Marks, the U.S. …

Despite DCGI Nod, Here’s Why Biological E's Corbevax is Not Yet Available for Booster Shots
2 years, 6 months ago

Despite DCGI Nod, Here’s Why Biological E's Corbevax is Not Yet Available for Booster Shots

News 18  

The wait for the roll-out of Biological E’s Corbevax vaccine as a heterologous booster shot may continue for a while, News18.com has learnt. Corbevax was approved for heterologous use as a Covid booster shot by apex drug regulator Drugs Controller General of India in the first week of June. Thankfully, Omicron does not cause severe disease and hence there is …

Allowing Corbevax as booster for those vaccinated with Coivishield, Covaxin likely to be considered by NTAGI
2 years, 6 months ago

Allowing Corbevax as booster for those vaccinated with Coivishield, Covaxin likely to be considered by NTAGI

The Hindu  

Allowing Biological E’s Corbevax as a booster for those fully vaccinated against COVID-19 with either Covishield or Covaxin is likely to be considered by the NTAGI, which is scheduled to meet on Tuesday, sources said. “The National Technical Advisory Group on Immunisation will discuss allowing Corbevax, which has been cleared by the DCGI, as a booster for those fully vaccinated …

Covaxin Effective Against Omicron Variants, Says ICMR as Sub-variants Driving up US Surge Found in Maha, Tamil Nadu
2 years, 6 months ago

Covaxin Effective Against Omicron Variants, Says ICMR as Sub-variants Driving up US Surge Found in Maha, Tamil Nadu

News 18  

The administration of Covaxin as a booster dose enhances vaccine effectiveness against Covid-19’s Delta variant and gives protection against Omicron variants BA.1.1 and BA.2, a study by ICMR and Bharat Biotech has found. “The evidence from the present study shows that Covaxin booster immunisation tends to broaden the protective immune response and reduces disease severity against the Delta and Omicron …

Corbevax gets DCGI nod as COVID-19 booster after two doses of Covishield or Covaxin
2 years, 7 months ago

Corbevax gets DCGI nod as COVID-19 booster after two doses of Covishield or Covaxin

The Hindu  

Hyderabad-based Biological E. Limited ’s COVID-19 vaccine Corbevax has been approved by the Drug Controller General of India as a heterologous COVID-19 booster dose to individuals aged 18 years and above after 6 months of administration of primary vaccination of Covaxin or Covishield vaccines for restricted use in emergency situations. ‘’Recently, BE furnished its clinical trials data to the DCGI, …

Corbevax Gets DCGI Approval As Covid-19 Vaccine Booster Dose For 18 Years And Above
2 years, 7 months ago

Corbevax Gets DCGI Approval As Covid-19 Vaccine Booster Dose For 18 Years And Above

ABP News  

New Delhi: The Drug Controller General of India approved the Corbevax Covid-19 booster as heterologous Covid-19 booster dose for adults above the age of 18 years who got their primary Covid-19 vaccination of Covishield or Covaxin administered six months before, reported news agency ANI. Recently, BE has furnished its clinical trials data to the DCGI who after a detailed evaluation …

Germany recognises Bharat Biotech's Covaxin for travel from June 1
2 years, 7 months ago

Germany recognises Bharat Biotech's Covaxin for travel from June 1

India TV News  

Highlights WHO in November last year issued an emergency use listing for Covaxin The step added a growing portfolio of vaccines validated for the prevention of COVID-19 WHO's EUL procedure assesses the quality, safety and efficacy of COVID-19 vaccines Germany has recognised the WHO-listed Bharat Biotech's COVID vaccine Covaxin, for travel to the country starting June 1. World Health Organization …

New oral Covid vaccine can decrease severity, transmission: Study
2 years, 8 months ago

New oral Covid vaccine can decrease severity, transmission: Study

India Today  

An investigational Covid vaccine designed to be administered orally has not only limited the degree of the disease but also decreased its airborne spread during its trial on animals, revealed a study published in the journal, Science Translational Medicine, earlier this week. The research team led by Duke University researcher Stephanie N Langel, a medical instructor in the Department of …

SII's Covid Vaccine Covovax Now Available for 12-17 Age Group at Private Centres
2 years, 8 months ago

SII's Covid Vaccine Covovax Now Available for 12-17 Age Group at Private Centres

News 18  

Children aged 12 to 17 years can now get the Serum Institute's coronavirus vaccine Covovax at private centres with a provision for it being made on the CoWIN portal, official sources said on Monday. "Those aged 12-17 age group can now opt for Covovax shot at private hospitals. India's drug regulator had approved Covovax for restricted use in emergency situations …

Covishield Has Least Neutralizing Power against Omicron’s BA.1 Variant, Boosters Needed: NIV Study
2 years, 8 months ago

Covishield Has Least Neutralizing Power against Omicron’s BA.1 Variant, Boosters Needed: NIV Study

News 18  

Covishield recipients with no history of Covid have shown the least neutralizing power against Omicron’s BA.1 variant, a study conducted by the ICMR-National Institute of Virology have found, indicating need for booster shots. Breakthrough cases jabbed with Covishield, however, had highest neutralizing antibodies against all variants studied, than recovered and Covid-naïve vaccinated individuals,” an ICMR scientist told The Times of …

India's 'warm vaccine' candidate effective against Delta, Omicron COVID-19 variants in mice, says study
2 years, 8 months ago

India's 'warm vaccine' candidate effective against Delta, Omicron COVID-19 variants in mice, says study

Firstpost  

The latest study, published recently in the journal Viruses, assessed vaccinated mice sera for efficacy against key coronavirus variants, including Delta and Omicron. New Delhi: A heat-stable COVID-19 vaccine that is being developed in India and does not need cold chain storage has generated a strong antibody response against coronavirus variants, including Delta and Omicron, according to a study on …

Indian Covid vaccines better than Pfizer, Moderna, says Adar Poonawalla
2 years, 8 months ago

Indian Covid vaccines better than Pfizer, Moderna, says Adar Poonawalla

India Today  

Serum Institute of India CEO Adar Poonawalla on Wednesday claimed that Covid-19 vaccines that are made in India, have provided more protection against coronavirus infection than vaccines like Pfizer and Moderna. Speaking to news agency ANI, Poonawalla said, "The Covid-19 vaccines which have been made in India are providing more protection against the disease than mRNA vaccines like Pfizer and …

Weighing the choices: on precautionary vaccine doses
2 years, 8 months ago

Weighing the choices: on precautionary vaccine doses

The Hindu  

As India sees a steady slump in its daily coronavirus count, the Centre has announced opening up the third, or ‘precautionary doses’, to everyone over 18 years. A major aspect of vaccines is the risk of adverse events following vaccination, and previous experience has suggested that certain vaccines may induce a higher risk of blood clots in younger populations. With …

High immune response to COVID variants in breakthrough cases after two Covaxin jabs: ICMR study
2 years, 9 months ago

High immune response to COVID variants in breakthrough cases after two Covaxin jabs: ICMR study

Firstpost  

The study highlights the significance of administering a booster dose or precaution dose of COVID vaccine as it provides better protection against the disease, said Dr Pragya Yadav, a senior scientist at NIV Pune and the lead investigator of the study New Delhi: In a recent ICMR study, breakthrough cases after full vaccination with Covaxin have shown a significant increase …

Bharat Biotech temporarily slows down Covaxin production for facility optimisation
2 years, 9 months ago

Bharat Biotech temporarily slows down Covaxin production for facility optimisation

India Today  

Bharat Biotech on Friday announced it was temporarily slowing down production of its Covid-19 vaccine, Covaxin, across its manufacturing facilities for facility optimisation as it had already completed its supply obligations to procurement agencies and foresaw a decrease in demand. "For the coming period, the company will focus on pending facility maintenance, process, and facility optimisation activities," Bharat Biotech said …

Bharat Biotech says slowing down Covaxin production for facility optimisation
2 years, 9 months ago

Bharat Biotech says slowing down Covaxin production for facility optimisation

India TV News  

Highlights Bharat Biotech said it is temporarily slowing down production of its COVID-19 vaccine Covaxin. Company said 'will focus on pending facility maintenance, process, facility optimisation activities' Bharat Biotech on Friday said it is temporarily slowing down production of its COVID-19 vaccine Covaxin across its manufacturing units for facility optimisation as it has already completed its supply obligations to procurement …

ICMR Study Has Shown Rise in Antibodies Post Covaxin Booster Dose: MoS Health Tells Rajya Sabha
2 years, 9 months ago

ICMR Study Has Shown Rise in Antibodies Post Covaxin Booster Dose: MoS Health Tells Rajya Sabha

News 18  

An ICMR study to examine the effect of Covaxin's booster dose has shown an increase in the levels of antibodies against SARS-CoV-2, Minister of State for Health Bharati Pravin Pawar told the Rajya Sabha on Tuesday. International data available on booster doses of AstraZeneca and Covishield suggests a three- to four-fold increase in antibody levels after their administration, Pawar said …

EU Drug Watchdog Approves AstraZeneca Covid Prevention Jab 'Evusheld'
2 years, 9 months ago

EU Drug Watchdog Approves AstraZeneca Covid Prevention Jab 'Evusheld'

News 18  

The EU’s drug watchdog on Thursday recommended for approval AstraZeneca’s Covid-19 prevention cocktail, which can be used for patients with immune system problems or severe reactions to other coronavirus vaccines. The European Medicines Agency’s human medicines committee “has recommended granting a marketing authorisation for Evusheld, developed by AstraZeneca for the prevention of Covid-19 in adults and adolescents from 12 years …

India's drugs regulator approves phase-3 trial of covid vaccine covovax
2 years, 9 months ago

India's drugs regulator approves phase-3 trial of covid vaccine covovax

India Today  

The Drugs Controller General of India granted permission on Wednesday for conducting the phase-3 clinical trial of Covid-19 vaccine Covovax as a booster dose in adults, official sources said. The Subject Expert Committee on Covid-19 of the Central Drugs Standard Control Organisation had, on March 5, recommended permission for conducting the phase-3 clinical trial for Covovax as a booster dose …

Better to err on the side of caution to ensure public health during pandemic, TN tells SC
2 years, 9 months ago

Better to err on the side of caution to ensure public health during pandemic, TN tells SC

The Hindu  

States like Tamil Nadu and Maharashtra in the Supreme Court on Tuesday justified their hardened stand to make COVID-19 inoculation mandatory, even at the cost of denying people their rights, by saying that it was better to err on the side of caution to prevent serious or irreversible harm to the public when there was insufficient information about the virus. …

Covishield as Booster After 2 Doses of Covaxin Increases Antibodies by 6 Times: Study
2 years, 9 months ago

Covishield as Booster After 2 Doses of Covaxin Increases Antibodies by 6 Times: Study

News 18  

A recent study has found that Covishield is more effective when administered as a booster after two doses of Covaxin as antibodies zoom six-fold, however, the case is not the same when the vaccines are reversed. The study, submitted by Christian Medical College, Vellore, to the Drugs Controller General of India on Wednesday, is the first preliminary scientific evidence from …

Discover Related